(421) A Novel Long-acting Injectable Formulation Enabling Sustained Release of Dutasteride over 3 months

Dutasteride, 5α-reductase inhibitor, blocks the conversion of testosterone to dehydrotestosterone (DHT), thereby lowering DHT levels in the blood. It is used to treat benign prostatic hyperplasia (BPH) and androgenic alopecia, but requires continuous daily administration for several months to be effective. Despite this limitations, no pharmaceutical technology has yet effectively improved medication compliance. Recently, Chong Kun Dang Corp. invented a lipid based long-acting injection (LAI) formulation of dutasteride enabling sustained release for over 3 months after a single administration.